Big Cypress Acquisition Corp. was founded by its founders with the goal of combining with a promising biotech company and putting it public. Then they had to locate it. By the time they were connected with Sioux Falls-based SAB Biotherapeutics, they had looked into dozens of biotech companies. SAB Biotherapeutics was the one that most closely met their criteria and became the focus of a process that is expected to lead to a Nasdaq listing before the end of the year.
Sam Reich, CEO, CFO and a board member of Big Cypress, the Florida-based special purpose acquisition company, or SPAC, said, “SAB stood out, and we got tremendously excited right away. We believe that SAB has a one-of-a-kind platform. Totally unique.” Due to Reich’s background, he was able to spot the difference right away.
After that, he made contact with a Harvard University neurology researcher who had created a revolutionary epilepsy treatment. The process of moving the possible new medicine closer to clinical trials and commercialization started over. Reich’s children were returning to school in Florida following pandemic-related homeschooling by the fall of 2020, and he was seeking for his next chance. The company’s staff was looking for a therapeutic company that had gone through safety testing but hadn’t yet reached commercialization.